Cerivastatin: the low-dose HMG-COA reductase inhibitor

Bibliography

• SHEPHERD J, COBBE SM, FORD I et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. (1995) 333:1301–1307.
   PubMed Web of Science ®Google Scholar
• DOWNS JR, CLEARFIELD M, WETS S et al.: Primaryprevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA (1998) 279:1615–1622.
   PubMed Web of Science ®Google Scholar
• SCANDINAVIAN SIMVASTATION SURVIVAL STUDYGROUP: Randomized trial of cholesterol lowering in 4444 participants with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344:1383–1389.
   PubMed Web of Science ®Google Scholar
• SACKS FM, PFEFFER MA, MOYE LA et al.: The effect ofpravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl. J. Med. (1996) 335:1001–1009.
   PubMed Web of Science ®Google Scholar
• THE LONG-TERM INTERVENTION WITH PRAVASTATININ ISCHAEMIC DISEASE (LIPID) STUDY GROUP: Preven-tion of cardiovascular events and death with pravas-tatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl. J. Med. (1998) 339:1349–1357.
   PubMed Web of Science ®Google Scholar
• FARNIER M, DAVIGNON J: Current and future treatment of hyperlipidemia: the role of statins. Am. J. Cardiol. (1998) 82:3J–10J.
   Google Scholar
• STEIN E: Cerivastatin in primary hyperlipidemia - a multicenter analysis of efficacy and safety. Atheroscle-rosis (1998) 139\(Suppl. 1):S15–S22.
   Google Scholar
• STEIN E, ISAACSOHN J, STOLTZ R et al.: Pharmacody-namics, safety, tolerability, and pharmacokinetics of the 0.8-mg dose of cerivastatin in patients with primary hypercholesterolemia. Am. J. Cardiol. (1999) 83:1433–1436.
   Google Scholar
• ROBERTS WC: The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am. J. Cardiol. (1997) 80:106–107.
   PubMed Web of Science ®Google Scholar
• HUNNINGHAKE DB: Clinical efficacy of cerivastatin:Phase Ha dose-ranging and dose-scheduling studies. Am. J. Cardiol. (1998) 82:26J–31J.
   Google Scholar
• NAWROCKI JW, WEISS SR, DAVIDSON MH et al.: Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler. Thromb. Vasc. Biol. (1995) 15:678–682.
   PubMed Web of Science ®Google Scholar
• DAVIDSON MG, STEIN EA, DUJOVNE CA et al.: The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am. J. Cardiol. (1997) 79:38–42.
   PubMed Web of Science ®Google Scholar
• BRADFORD RH, SHEAR CL, CHREMOS AN et al.: Expanded clinical evaluation of lovastatin (EXCEL) study results. I: Efficacy in modifying plasma lipopro-teins and adverse event profile in 8245 patients with moderate hypercholesterolaemia. Arch. Intern. Med. (1991) 151:43–49.
   Google Scholar
• ISAACSOHN J, STEIN E, WEINSTEIN R et al.: Cerivastatin,a novel potent HMG-CoA reductase inhibitor: comparative efficacy versus fluvastatin. 13th Interna-tional Symposium on Drugs Affecting Lipid Lowering. Florence, Italy (30 May - 31 June 1998). Abstract 62.
   Google Scholar
• ZAVORAL JH, HAGGERTY BJ, WINICK AG et al: Efficacy of fluvastatin, a totally synthetic 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor. Am. J. Cardiol. (1995) 76 (Suppl.):37A–40.
   Google Scholar
• KNOPP RH, BROWN WV, CORDER CN et al.: Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholestero-laemia. Arch. Intern. Med. (1993) 153:1321–1329.
   PubMed Web of Science ®Google Scholar
• PEDERSEN TR: Design and baseline results of the Scandinavian simvastatin survival study of patients with stable angina and/or previous myocardial infarc-tion. The Scandinavian Simvastatin Survival Study Group. Am. J. Cardiol (1993) 71:393–400.
   Google Scholar
• STEIN E, SPRECHER D, ALLENBY KS et al.: Cerivastatin, a new potent synthetic HMG Co-A reductase inhibitor: effect of 0.2 mg daily in subjects with primary hypercholesterolemia. J. Cardiovasc. Pharmacol. Ther. (1997) 2:7–16.
   Google Scholar
• CORSINI A, ARNABOLDI A, RAITERI M et al. Effect of the new HMG-CoA reductase inhibitor cerivastatin (BAY W 6228) on migration, proliferation and cholesterol synthesis in arterial myocytes. Pharmacol Res. (1996) 33 55–61
   PubMed Web of Science ®Google Scholar
• BISCHOFF H, ANGERBAUER R, BENDER J et al.: Cerivas-tatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor. Atherosclerosis (1997) 135:119–130.
   PubMed Web of Science ®Google Scholar
• IGARASHI M, TAKEDA Y, MORI S et al.: Suppression of neointimal thickening by a newly developed HMG-CoA reductase inhibitor, BAY w6228, and its inhibitory effect on vascular smooth muscle cell growth. Br. J. Pharmacol. (1997) 120:1172–1178.
   PubMed Web of Science ®Google Scholar
• SHIOMI M, ITO T: Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits. Br. J. Pharmacol. (1999) 126:961–968.
   PubMed Web of Science ®Google Scholar
• PEDERSEN TR, TOBERT JA: Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease. A review. Drug Safety (1996) 14 (1):11–24.
   PubMed Web of Science ®Google Scholar
• MUCK W, RITTER W, DIETRICH H et al: Influence of the antacid Maaloz® and the 112-antagonist cimetidine on the pharmacokinetics of cerivastatin. Int. J. Clin. Pharmacol. Ther. (1997) 35:261–264.
   PubMed Web of Science ®Google Scholar
• RITTER W, FREY R, KROL G et al.: Single dose pharma-cokinetics of rivastatin, a novel HMG-CoA reductase inhibitor. Naunyn-Schmiedeberg's Arch. Pharmacol. (1993) 347 (Suppl.):R39.
   Google Scholar
• RITTER W, FREY R, KROL G et al: Rivastatin single dose pharmacokinetics. Clin. Pharmacol. Ther. (1993) 53:210.
   Web of Science ®Google Scholar
• STEINKE W, YAMASHITA S, TABEI M et al.: Cerivastatin, a new inhibitor of HMG-CoA reductase. Pharmacoki-netics in rats and dogs. Jpn. Pharmacol. Ther. (1996) 24 (Suppl. 9):1217–1243.
   Google Scholar
• SHIMADA T, YAMAZAKI H, MIMURA M et al.: Interindi-vidual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcino-gens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. (1994) 270:414–423.
   PubMed Web of Science ®Google Scholar
• GUENGERICH FP: In vitro techniques for studying drugmetabolism. J. Pharmacokinet. Biopharm. (1996) 24:521–533.
   PubMedGoogle Scholar
• KANTOLA T, KIVISTO KT, NEUVONEN PJ: Effect of itraconazole on cerivastatin pharmacokinetics. Eur. J. Pharmacol. (1999) 54:851–855.
   Web of Science ®Google Scholar
• BISCHOFF H, ANGERBAUER R, BOBERG M et al.: Preclinical review of cerivastatin sodium - a step forward in HMG-CoA reductase inhibition. Atheroscle-rosis (1998) 139 (Suppl. 1):S7–13.
   Google Scholar
• BOBERG M, ANGERBAUER R, KANHAI W et al.: [14C]BAYw 6228: Biotransformation in human liver microsomes in vitro. Characterization of primary metabolite pathways and of cytochrome P450 isozymes involved. Drug Metab. Dispos. (1997) 25:321–331.
   Google Scholar
• SPACH DH, BAUWENS JE, CLARK CD et al.: Rhabdomy-olysis associated with lovastatin and erythromycin use. West. J. Med. (1991) 154:213–215.
   PubMedGoogle Scholar
• LEES RS, LEES AM: Rhabdomyolysis from the coadmin-istration of lovastatin and the antifungal agent itraconazole. N Engl. J. Med. (1995) 333:664–665.
   PubMed Web of Science ®Google Scholar
• NEUVONEN PJ, JALAVA KM: Itraconazole drastically mereases plasma concentrations of lovastatin and lovastatin acid. Clin. Pharmacol Ther. (1996) 60:54–61.
   PubMed Web of Science ®Google Scholar
• NEUVONEN PJ, KANTOLA T, KIVISTO TK: Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Pharmacol. Ther. (1998) 63:332–341.
   Web of Science ®Google Scholar
• KANTOLA T, KIVISTO KT, NEUVONEN PJ: Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin. Pharmacol Ther. (1998) 63:397–402.
   PubMed Web of Science ®Google Scholar
• MUCK W, OCHMANN K, ROHDE G et al: Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin. Eur. j Clin. Pharmacol. (1998) 53:469–473.
   PubMed Web of Science ®Google Scholar
• SCHALL R, MUELLER FO, HUNDT HK et al: No pharma-cokinetic or pharmacodynamic interaction between rivastatin and warfarin. J. Clin. Pharmacol. (1995) 35:306–313.
   PubMed Web of Science ®Google Scholar
• OLBRICHT C, WANNER C, EISENHAUER T et al: Accumu-lation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin. Pharmacol Ther. (1998) 62:311–321.
   Web of Science ®Google Scholar
• MAT I, BAUER S, FRITSCHE J et al.: Clinical pharmacoki-netics of new HMG-CoA reductase inhibitor in renal transplant patients treated with cyclosporine A (CSA). Eur. J. Clin. Pharmacol. (1997) 52 (Suppl. A137). Abstract 419.
   Google Scholar
• MUCK W, OCHMANN K, ROHDE G et al.: No drug-drug interaction between cerivastatin and omeprazole. Naunyn-Schmiedeberg's Arch. Pharmacol. (1998) 357(Suppl.):R175.
   Google Scholar
• SACHSE R, BRENDEL E, MUCK W et al: No drug-drug interation between cerivastatin and nifedipine. Naunyn-Schmiedeberg's Arch. Pharmacol. (1998) 357(Suppl.):R174.
   Google Scholar
• LETTIERI J, KROL G, MAZZU A et al.: Lack of pharmacoki-netic interaction between cerivastatin, a new HMG-CoA reductase inhibitor, and digoxin. Atheroscle-rosis (1997) 130 (Suppl.):S29–A109.
   Google Scholar
• STEIN EA: Extending therapy options in treating lipid disorders. A clinical review of cerivastatin, a novel HMG CoA reductase inhibitor. Drugs (1998) 56 (Suppl. 1)25–31.
   Google Scholar